EUCTR2020-002917-16-IT进行中（未招募）1 期
An Open-Label, Multicenter, Follow-up Trial of ARGX-113-1904 to Evaluate the Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients with Pemphigus - ADDRESS+
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- ARGENX BV
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Participants must meet all of the following inclusion criteria:
- •1. Ability to understand the requirements of the trial, to provide written informed consent (including consent for the use and disclosure of research-related health information), willingness and ability to comply with the trial protocol procedures (including required trial visits).
- •2. The patient participated in trial ARGX-113-1904 and completed the study or has the defined criteria for rollover.
- •3. Women of childbearing potential:
- •a. Must have a negative urine pregnancy test at baseline before trial medication can be administered.
- •b. Must be on a stable regimen for at least 1 month of at least 1 highly effective method of contraception (ie, failure rate of less than 1% per year) during the trial and for 90 days after the last administration of IMP.
- •4. Non-sterilized male patients who are sexually active with a female partner of childbearing potential must use effective contraception from first administration of IMP through 90 days after the last administration of the IMP. Male patients practicing true sexual abstinence (as consistent with preferred and usual life style) can be included. Sterilized male patients who have had a vasectomy and with documented absence of sperm post-procedure can be included. Male patients are not allowed to donate sperm from first administration of IMP through 90 days after the last dose of IMP.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 105
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 45
排除标准
- •Participants are excluded from the trial if any of the following criteria apply:
- •1. Pregnant and lactating women and those intending to become pregnant during the trial or within 90 days after the last administration of IMP.
- •2. Patients with clinical evidence of other significant serious disease or patients who recently underwent or have planned a major surgery during the period of the trial, or any other condition in the opinion of the investigator, that could confound the results of the trial or put the patient at undue risk.
- •3. Known hypersensitivity to any of the components of the administered treatments.
研究者
相似试验
进行中（未招募）
1 期
A study to assess the safety and efficacy of a subcutaneous formulation of efgartigimod PH20 SC in adults with Pemphigus (Vulgaris or Foliaceus)EUCTR2020-002917-16-HUargenx BV180
进行中（未招募）
1 期
A study to assess the safety and efficacy of a subcutaneous formulation of efgartigimod PH20 SC in adults with Pemphigus (Vulgaris or Foliaceus)Pemphigus Vulgaris or Pemphigus FoliaceusMedDRA version: 20.0Level: LLTClassification code 10052802Term: Pemphigus vulgarisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 20.0Level: LLTClassification code 10057069Term: Pemphigus foliaceusSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2020-002917-16-GRargenx BV180
进行中（未招募）
1 期
A study to assess the safety and efficacy of a subcutaneous formulation of efgartigimod PH20 SC in adults with Pemphigus (Vulgaris or Foliaceus)Pemphigus Vulgaris or Pemphigus FoliaceusMedDRA version: 20.0Level: LLTClassification code 10052802Term: Pemphigus vulgarisSystem Organ Class: 100000004858MedDRA version: 20.0Level: LLTClassification code 10057069Term: Pemphigus foliaceusSystem Organ Class: 100000004858EUCTR2020-002917-16-BGargenx BV180
进行中（未招募）
3 期
Open-label follow-up trial of ARGX-113-1904JPRN-jRCT2031210277Aoyama Yumi12
进行中（未招募）
1 期
A study to assess the safety and efficacy of a subcutaneous formulation of efgartigimod PH20 SC in adults with Pemphigus (Vulgaris or Foliaceus)EUCTR2020-002917-16-DEargenx BV180